Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Novo Nordisk’s stock fell significantly today, reaching a low of $81 per share. This triggered an oversold signal, with its Relative Strength Index (RSI) dropping to 28.6 In contrast ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...

I’m cautious about Novo Nordisk's stock in the short term due ... and cagrilintide (amylin analog), targeting weight loss and glycemic control. Phase 2 trial was completed in August 2022 ...

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE:NVO) following recent industry developments and competitive insights. The firm said in a note ...